Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement

British Journal of Dermatology

Volumn 162, Issue 6, 2010, Pages 1216-1223

  Soegaard Madsen, L ^a   Johansen, C ^a   Iversen, L ^a   Kragballe, K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adalimumab; P38 mitogen activated protein kinase; Psoriasis

Indexed keywords

ADALIMUMAB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; REACTION TIME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; TISSUE LEVEL; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; BLOTTING, WESTERN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PSORIASIS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952677598     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09706.x     Document Type: Article

References (34)

1. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
2. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008 117 : 244 279.
3. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999 38 : 241 251.
4. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 151.
5. Aggarwal BB, Shishodia S, Takada Y et al. TNF blockade: An inflammatory issue. In : Cytokines as Potential Therapeutic Targets for Inflammatory Skin Diseases. Ernst Schering Research Foundation Workshop (Numerof R, Dinarello CA, Asadullah K, eds).
6. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003 21 : 392 397.
7. Valesini G, Iannuccelli C, Marocchi E et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007 7 : 35 41.
8. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
9. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
10. Revicki DA, Willian MK, Menter A et al. Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007 18 : 341 350.
11. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
12. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007 48 : 87 101.
13. Gordon KB, Bonish BK, Patel T et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005 153 : 945 953.
14. Shen C, van Assche G, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005 21 : 251 258.
15. Shen C, van Assche G, Rutgeerts P et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006 12 : 22 8.
16. Johansen C, Kragballe K, Westergaard M et al. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005 152 : 37 42.
17. Takahashi H, Ibe M, Nakamura S et al. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002 30 : 94 9.
18. Yu XJ, Li CY, Dai HY et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007 83 : 413 418.
19. Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2012 2019.
20. Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 2006 126 : 1784 1791.
21. Johansen C, Funding AT, Otkjaer K et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006 176 : 1431 1438.
22. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004 68 : 320 344.
23. Johansen C, Flindt E, Kragballe K et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005 124 : 1284 1292.
24. Johansen C, Moeller K, Kragballe K et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2857 2864.
25. Kragballe K, Desjarlais L, Marcelo CL. Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 1985 112 : 263 270.
26. 3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes. J Invest Dermatol 2003 120 : 561 570.
27. U.S. Food and Drug Administration. Adalimumab Product Approval Information. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080610.htm (last accessed 8 February 2010).
28. Iversen L, Johansen C, Kragballe K. Signal transduction pathways in human epidermis. Eur J Dermatol 2005 15 : 4 12.
29. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008 58 : 1248 1257.
30. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007 13 : 1323 1332.
31. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 175 : 2721 2729.
32. Garfield BE, Krahl T, Appel S et al. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis. Clin Immunol 2005 116 : 101 107.
33. Aerts NE, Ebo DG, Bridts CH et al. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): P38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis. Cytokine 2009 47 : 178 184.
34. Semmler M, Seeck U, Neustadt B et al. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 2007 26 : 1499 1504.